Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts

Chen,Shan; Liu,Xiaoxia; Gong,Wenfei; Yang,Huan; Luo,Daofei; Zuo,Xialin; Li,Wenshi; Wu,Ping; Liu,Li; Xu,Qian; Ji,Aimin

doi:10.3892/or.2012.2097

Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts

Authors:
- Shan Chen
- Xiaoxia Liu
- Wenfei Gong
- Huan Yang
- Daofei Luo
- Xialin Zuo
- Wenshi Li
- Ping Wu
- Li Liu
- Qian Xu
- Aimin Ji
View Affiliations

Affiliations: Department of Pharmaceutical Science, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, P.R. China
Published online on: October 19, 2012 https://doi.org/10.3892/or.2012.2097
Pages: 260-268

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

RNA targeting the murine vascular endothelial growth factor receptor 2 (VEGFR2) gene was designed and validated for efficient and robust silencing in vitro and was delivered by polyethylenimines (PEI) in vivo to investigate the antitumor effect on non-small cell lung cancer (NSCLC) xenografts. The following dosage regimens were tested for their tumor inhibitory effect in vivo: VEGFR2 siRNA, epidermal growth factor receptor (EGFR) siRNA, VEGFR2 siRNA+EGFR siRNA, cisplatin alone and VEGFR2 siRNA+ EGFR siRNA+cisplatin. Targeted silencing of both VEGFR2 and EGFR expression by siRNA, combined with low-dose cisplatin, was found to effectively inhibit tumor growth and extend the survival time of mice bearing the NSCLC xenografts. These results suggest that combination therapy using siRNAs and chemotherapy agents might offer a novel strategy for cancer treatment in the future.

View Figures

View References

1	Gimbrone MA, Leapman SB Jr, Cotran RS, et al: Tumor dormancy in vivo by prevention of neovascularization. J Exp Med. 136:261–276. 1972. View Article : Google Scholar : PubMed/NCBI
2	Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003. View Article : Google Scholar
3	Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007. View Article : Google Scholar : PubMed/NCBI
4	Brown LF, Detmar M, Claffey K, et al: Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS. 79:233–269. 1997.PubMed/NCBI
5	Herbert SP and Stainier DY: Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol. 1:551–564. 2011. View Article : Google Scholar : PubMed/NCBI
6	Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 5:341–354. 2005. View Article : Google Scholar : PubMed/NCBI
7	Wells A: EGF receptor. Int J Biochem Cell Biol. 31:637–643. 1999. View Article : Google Scholar
8	Ciardiello F and Tortora G: Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer. 39:1348–1354. 2003. View Article : Google Scholar
9	Morelli MP, Cascone T, Troiani T, et al: Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. J Cell Physiol. 208:344–353. 2006. View Article : Google Scholar : PubMed/NCBI
10	Nicholson RI, Gee JM and Harper ME: EGFR and cancer prognosis. Eur J Cancer. 37(Suppl 4): S9–S15. 2001. View Article : Google Scholar
11	Kerbel RS: Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science. 312:1171–1175. 2006. View Article : Google Scholar : PubMed/NCBI
12	Dancey JE and Freidlin B: Targeting epidermal growth factor receptor - are we missing the mark? Lancet. 362:62–64. 2003. View Article : Google Scholar : PubMed/NCBI
13	Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 349:427–434. 2003. View Article : Google Scholar : PubMed/NCBI
14	Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
15	Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
16	Wang Y, Li Z, Han Y, et al: Nanoparticle-based delivery system for application of siRNA in vivo. Curr Drug Metab. 11:182–196. 2010. View Article : Google Scholar : PubMed/NCBI
17	Oh YK and Park TG: siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev. 6:850–862. 2009.
18	Castanotto D and Rossi JJ: The promises and pitfalls of RNA-interference-based therapeutics. Nature. 457:426–433. 2009. View Article : Google Scholar : PubMed/NCBI
19	Urban-Klein B, Werth S, Abuharbeid S, et al: RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 12:461–466. 2005. View Article : Google Scholar : PubMed/NCBI
20	Boussif O, Lezoualc’h F, Zanta MA, et al: A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA. 92:7297–7301. 1995. View Article : Google Scholar : PubMed/NCBI
21	Franklin WA, Veve R, Hirsch FR, et al: Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol. 29:3–14. 2002. View Article : Google Scholar : PubMed/NCBI
22	Tuschl T, Zamore PD, Lehmann R, et al: Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev. 13:3191–3197. 1999. View Article : Google Scholar : PubMed/NCBI
23	Schiffelers RM, Ansari A, Xu J, et al: Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32:e1492004. View Article : Google Scholar
24	Weihua Z, Tsan R, Huang WC, et al: Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell. 13:385–393. 2008. View Article : Google Scholar : PubMed/NCBI
25	Tan Y, Sun X, Xu M, et al: Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice. Clin Cancer Res. 5:2157–2163. 1999.PubMed/NCBI
26	Bruyere C, Lonez C, Duray A, et al: Considering temozolomide as a novel potential treatment for esophageal cancer. Cancer. 117:2004–2016. 2010. View Article : Google Scholar : PubMed/NCBI
27	Yang H, Che O, Chen S, et al: Silence of VEGFR2 expression mediated by PEI/siRNA complexes. Yao Xue Xue Bao. 45:576–581. 2010.(In Chinese).
28	Dvorak HF: Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 315:1650–1659. 1986. View Article : Google Scholar : PubMed/NCBI
29	Risau W: Mechanisms of angiogenesis. Nature. 386:671–674. 1997. View Article : Google Scholar : PubMed/NCBI
30	Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
31	Murukesh N, Dive C and Jayson GC: Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer. 102:8–18. 2010. View Article : Google Scholar : PubMed/NCBI
32	Nyberg P, Xie L and Kalluri R: Endogenous inhibitors of angiogenesis. Cancer Res. 65:3967–3979. 2005. View Article : Google Scholar : PubMed/NCBI
33	Ohsaki Y, Tanno S, Fujita Y, et al: Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep. 7:603–607. 2000.PubMed/NCBI
34	Wu W, Onn A, Isobe T, et al: Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther. 6:471–483. 2007. View Article : Google Scholar
35	Slaton JW, Perrotte P, Inoue K, et al: Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res. 5:2726–2734. 1999.PubMed/NCBI
36	Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI
37	Hanahan D, Bergers G and Bergsland E: Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 105:1045–1047. 2000. View Article : Google Scholar : PubMed/NCBI
38	Jain RK: Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park). 19:7–16. 2005.PubMed/NCBI
39	Higgins KJ, Abdelrahim M, Liu S, et al: Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins. Biochem Biophys Res Commun. 345:292–301. 2006. View Article : Google Scholar : PubMed/NCBI
40	Hobel S, Koburger I, John M, et al: Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. J Gene Med. 12:287–300. 2010.